DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Orteronel
Orteronel
A Phase 1 Multiple-Dose Study of Orteronel in Japanese Patients with Castration-Resistant Prostate Cancer
(19) United States (12) Patent Application Publication (Io) Pub
Galeterone for the Treatment of Castration- Resistant Prostate Cancer Bruce Montgomery1, Mario A
WO 2018/111890 Al 21 June 2018 (21.06.2018) W !P O PCT
Tanibirumab (CUI C3490677) Add to Cart
Therapies Targeted to Androgen Receptor Signaling Axis in Prostate Cancer: Progress, Challenges, and Hope
Orteronel for Metastatic Hormone-Relapsed Prostate Cancer
Download Product Insert (PDF)
Prostate Cancer
Role of Heat Shock Protein 27 and Lyn Tyrosine Kinase in Regulation of Androgen Receptor Expression and Activity in Prostate Cancer
Application for Enzalutamide and Abiraterone Acetate
Resistance to Second Generation Antiandrogens in Prostate Cancer: Pathways and Mechanisms
Stembook 2018.Pdf
Changing Paradigms in Management of Metastatic Castration Resistant Prostate Cancer (Mcrpc) Eva Gupta1*, Troy Guthrie2 and Winston Tan1
Emerging Drugs for Prostate Cancer
Drug Repurposing for Triple-Negative Breast Cancer
A Phase II Study of Increased-Dose Abiraterone Acetate in Patients with Castration Resistant Prostate Cancer (CRPC)
Orteronel Plus Prednisone in Patients with Chemotherapy
Top View
Androgen Receptor: Structure, Role in Prostate Cancer and Drug Discovery
WO 2017/180086 Al 19 October 2017 (19.10.2017) P O P C T
Androgen Receptor Antagonism Drives Cytochrome P450 17A1 Inhibitor Efficacy in Prostate Cancer
Phase 1/2 Trial of Orteronel (TAK-700) – an Investigational 17,20-Lyase
11~) United States 112) Patent Application Publication 110) Pub
Download Author Version (PDF)
UCSF Genitourinary Medical Oncology Program Advanced
Androgen Receptor Antagonism Drives Cytochrome P450 17A1 Inhibitor Efficacy in Prostate Cancer
3867.Full-Text.Pdf
TAK-700) in Patients with Nonmetastatic Castration-Resistant Prostate Cancer and Rising Prostate-Specific Antigen
Eighty Years of Targeting Androgen Receptor Activity in Prostate Cancer: the Fight Goes On
Cancer Therapy: Clinical [Uninvited] Running Title: Galeterone for Metastatic Castration Resistant Prostate Cancer
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Strategies to Circumvent Testosterone Surge and Disease Flare in Advanced Prostate Cancer: Emerging Treatment Paradigms
Enzalutamide in the Who Model List of Essential Medicines for the Treatment of Metastatic Castration Resistant Prostate Cancer
Prospective Evaluation of Low-Dose Ketoconazole Plus Hydrocortisone in Docetaxel Pre-Treated Castration-Resistant Prostate Cancer Patients
Emerging Therapeutic Approaches in the Management of Metastatic Castration-Resistant Prostate Cancer
A Population Pharmacokinetic Analysis of the Oral CYP17 Lyase
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Heart Failure and Atrial Tachyarrhythmia on Abiraterone: A
Clinical Trials in Progress 6
Orteronel Switch Maintenance Therapy in Metastatic Castration
Current Role of Diethylstilbestrol in the Management of Advanced Prostate Cancer
Androgen Receptor Antagonists for Prostate Cancer Therapy
Comparing the Clinical Efficacy of Abiraterone Acetate, Enzalutamide
Targeting the PI3K/Akt/Mtor Pathway in Castration-Resistant Prostate Cancer
Product Data Sheet
Inhibiting Steroid Biosynthesis in Prostate Cancer
Structural and Functional Evaluation of Clinically Relevant Inhibitors of Steroidogenic Cytochrome P450 17A1